Citi raised the firm’s price target on 10x Genomics (TXG) to $24 from $18 and keeps a Neutral rating on the shares. The firm adjusted targets in the life science tools and diagnostics group as part of a Q1 preview. Citi is seeing interest in the group pick back up “modestly” following the recent sector selloff.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics upgraded to Outperform from Market Perform at William Blair
- Is Cathie Wood Turning Bearish on Bullish (BLSH) Stock?
- FIG, CRCL, BLSH: Why Cathie Wood Just Bet $8M on Figma Despite Google’s (GOOGL) New Threat, Sells Crypto Stocks
- Cathie Wood’s ARK Investment buys 92K shares of 10x Genomics today
- 10x Genomics falls -13.8%